SCHEMBL2653350

SCHEMBL2653350

O=Cc1ccc2c(c1)ncn2-c1cccc(COCc2ccncn2)c1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 10/20 0.47
ALDH1A1 P00352 3/20 0.37
HPGD P15428 3/20 0.37
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
MAPT P10636 1/20 0.37
MAPK1 P28482 1/20 0.37
HTT P42858 1/20 0.37
RAB9A P51151 1/20 0.37
KMT2A Q03164 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
GABRA1 P14867 1/20 0.35
GABRG2 P18507 1/20 0.35
GABRB3 P28472 1/20 0.35
GABRA5 P31644 1/20 0.35
GABRA3 P34903 1/20 0.35
GABRA2 P47869 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2654799 0.88 FGFR1 (0.51) FGFR1ALDH1A1KDM4EMEN1MAPT
SCHEMBL2653453 0.88 GABRA1 (0.37) FGFR1ALDH1A1HPGDKDM4EMEN1
SCHEMBL2979088 0.85 FGFR1 (0.49) FGFR1ALDH1A1HPGDKDM4EMEN1
SCHEMBL2652953 0.84 FGFR1 (0.39) FGFR1ALDH1A1HPGDKDM4EMEN1
SCHEMBL2652387 0.84 KIT (0.39) FGFR1ALDH1A1HPGDKDM4EMEN1
SCHEMBL2652340 0.81 FGFR1 (0.47) FGFR1ALDH1A1HPGDKDM4EMEN1
SCHEMBL2654547 0.80 HPGD (0.46) FGFR1ALDH1A1HPGDMEN1MAPK1
SCHEMBL2654103 0.80 FGFR1 (0.46) FGFR1ALDH1A1HPGDKMT2A
SCHEMBL2969668 0.80 FGFR1 (0.46) FGFR1ALDH1A1HPGDKMT2AGABRA1
SCHEMBL2966387 0.80 KMT2A (0.48) FGFR1ALDH1A1HPGDMEN1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776900-B2 Benzimidazole derivatives and their use for modulating the GABAAreceptor complex NEUROSEARCH A/S (DK) 2010-08-17 US disclosed
US-20090030018-A1 Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex ANIONA APS (DK) 2009-01-29 US disclosed
EP-1874758-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX NEUROSEARCH A/S (DK) 2008-01-09 EP disclosed
WO-2006111516-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX NEUROSEARCH A/S (DK) 2006-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030018-A1 Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex GABRB2, GABRB1, GABRB3 FGFR1 4324/4885ALDH1A1 600/4885HPGD 1855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.